AI assistant
Sending…
BioLineRx Ltd. — Capital/Financing Update 2020
May 28, 2020
6692_rns_2020-05-28_ded98327-4ef1-4505-9d02-4a6ec01d488f.htm
Capital/Financing Update
Open in viewerOpens in your device viewer
BioLine announces the closing of its previously announced $9.0 million registered direct offering false
| ������� �� ��� ��"� | 2 380 |
| BIOLINE RX LTD | |
| Corporation no: 513398750 | 9253 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 28/05/2020 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2020-02-047941 | Time of broadcast: 19:15 19:14:21 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onBioLine announces the closing of its previously announced $9.0 million registered direct offering
6-K_closing_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 22/04/2020 |
| Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101 | |
| E-mail address: [email protected] Company site: www.biolinerx.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company: | |
| Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1 | |
| Israel |
More from BioLineRx Ltd.
Report Publication Announcement
2026
May 24
Regulatory Filings
2026
May 24
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 19
Report Publication Announcement
2026
May 19
Regulatory Filings
2026
May 19
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 28
Report Publication Announcement
2026
Apr 28
Regulatory Filings
2026
Mar 29